The United Kingdom and the United States have announced a significant trade agreement that will guarantee zero levies on UK pharmaceutical shipments entering the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This move ensures that import taxes on these crucial products will be held at zero for a timeframe of 36 months.
This development comes after previous threats to dramatically increase import taxes on patented pharmaceutical imports, with increases discussed reaching one hundred percent.
"This arrangement between the Britain strengthens the worldwide climate for innovative medicines and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," a statement declared.
Economic Significance
Pharmaceuticals are one of the the United Kingdom's largest export categories to the United States, which is clearly the biggest market for large companies like GSK and AstraZeneca.
Export figures show that in the 12 months to the end of September, the UK exported pharmaceutical products totaling £11.1bn to the US. This amount accounted for a significant portion of British export trade in that timeframe.
"This agreement protects jobs, increases investment and facilitates the UK to become a global hub for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The agreement includes several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to increase total NHS spending on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at 15%. Previously, rebates exceeded twenty percent.
Broader Context
The deal takes place against a protracted row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were exacerbated by assertions that American patients were charged several times more for the identical medicines than patients in the Britain and the EU.
Recently, several major drug company projects in the UK have been halted or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
One official publicly accepted that the NHS had to invest a greater share on drugs, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
